Relapsed or Refractory B-cell Lymphoma
Conditions
Brief summary
PD1 pathway is critical in determining the response to CAR T cell therapy. Emerging data suggested that Inhibition of PD1 could enhance the efficacy of CAR T cell therapy. iPD1 CD19 eCAR T cells is an enhanced version of the classical 2nd generation anti-CD19 4-1BB-costimulatory chimeric antigen receptor engineered T cells with cell-intrinsic PD1 inhibition by incorporation of a PD1 shRNA-expressing cassette in the CAR lentivector. This design will enhance the anti-tumor activities of CAR T cells by inhibiting PD1 induction after CAR T cell activation. This pilot, single arm, one center, dose-escalation, open label study is to determine the safety and efficacy of iPD1 CD19 eCAR T cells in relapsed or refractory CD19 positive lymphoma. Subjects will be given a lymphodepletion chemotherapy comprised of Fludarabine and cyclophosphamide prior to CAR T cell infusion. The chemotherapy is completed 1 to 4 days before the first dost of iPD1 CD19 eCAR T cells.
Interventions
BIOLOGICALiPD1 CD19 eCAR T cells
iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）. CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg
Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
Sponsors
Marino Biotechnology Co., Ltd.
Peking University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. CD19+ B cell lymphoma,verified by IHC or flow cytometry. 2. a prior history of at least one standard care of medication. 3. ineligible for allogeneic transplantation or relapsed after transplantation. 4. patients are 18 years older. 5. life expectancy \> 3months. 6. ECOG ≤ 2. 7. satisfactory major organ functions: adequate heart function with LVEF≥50%; pulse oximetry of ≥ 90%; cockcroft-gault creatinine clearance≥40 ml/min; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3ULN; Bilirubin ≤2.0 mg/dl . 8. Blood: Hgb ≥ 80 g/L, ANC ≥ 1×10\^9/L, PLT ≥ 50×10\^9/L. 9. women of reproductive potential must have a negative pregnancy test. Male and female of reproductive potential must agree to use birth control during the study and one year post study. 10. measurable tumors.
Exclusion criteria
1. using immunosuppressive drugs or systemic steroids within one week of enrollment. 2. active infection. 3. HIV positive. 4. active hepatitis B virus infection or hepatitis C virus infection. 5. breastfeeding or pregnant women. 6. patients refuse to practice birth control during study and one year post study. 7. patients with a prior history of other malignances will be excluded from this study, but patients who have been cured from skin basal cell carcinoma or cervical cancer, or who have had their tumors removed by surgical resection but without further therapies and have more than 5 years of progression-free survival, can be included into the study. 8. currently enrolled in other study. 9. patients, in the opinion of investigators, may not be eligible or are not able to comply with the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety of infusion of iPD1 CD19 eCAR T cells as assessed by the incidents of treatment related adverse events per NCI CTCAE V4.0 | 2 years | incidents of treatment related adverse events per NCI CTCAE V4.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| treatment response | 6 months | The efficacy of infusion of iPD1 CD19 eCAR T cells is assessed according to the standardized response criteria for malignant lymphoma (Cheson BD, JCO, 2007), which is defined as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD). |
| overall survival | 3 years | Overall survival is defined as the time from receiving iPD1 CD19 eCAR T cells infusion to death for any cause. |
| progression-free survival | 2 years | Progression-free survival (PFS) is defined as the time from receiving iPD1 CD19 eCAR T cell infusion to disease progression or death from any cause. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Persistence of iPD1 CD19 eCAR T cells in patients | 2 years | measured by quantitative PCR |
| proliferation of iPD1 CD19 eCAR T cells in patients | 6 months | measured by flow cytometry |
Countries
China
Contacts
Primary ContactJun Zhu, MD
Backup ContactZhitao Ying, MD
Outcome results
None listed